Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...
Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...
The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...
Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...
News-Medical.Net on MSN
Durvalumab extends survival in small cell lung cancer but raises cost concerns
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...
From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month ...
Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
Researchers have identified a previously unknown inflammatory mechanism that may drive the aggressiveness and relapse of ...
Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback